Bioverativ taps patient social network for input on hemophilia trial design

Hemophilia A Iceberg
Bioverativ designed a hemophilia drug trial to address newly unearthed unmet needs, by gauging pain in addition to bleeding.

What if companies knew patients’ top treatment priorities before clinical trials started—and could factor those unmet needs into study designs? Bioverativ is about to find out.

While designing an upcoming trial for a new hemophilia drug, the Biogen spinoff tapped patient social network creator MyHealthTeams to help find out what ailed hemophilia patients after their bleeding was controlled. The goal was to understand unmet patient needs and work them into the trial, potentially enabling marketers to eventually talk up those very benefits down the line.

The findings? Fifty-six percent of respondentsall from MyHealthTeams’ MyHemophiliaTeam networkreported ongoing pain, and, given that pain, 65% said they needed help with depression. And Bioverativ, in turn, designed its trial to address those unmet needs by gauging pain in addition to bleeding.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

RELATED: Biogen CEO eyes value-based payer deals to boost pressured MS franchise

Bioverativ first partnered with MyHealthTeams a couple of years back, intent on making sure the studies the company pursued “actually matter” to patients with the disease, MyHealthTeams cofounder Eric Peacock said in an interview.

In the process, the company picked up some potential endpoints that could matter to regulators and payers, too, he noted. If Bioverativ were to include pain in a trial and come up successful, “that means their FDA-approved label could have and speak to issues of pain, and there’s no other drug in the market that does that,” Peacock said.

“It really differentiates their drug by addressing the No. 1 complaint of all these patients, and unless it’s in a trial, you can’t talk about it,” he added.

RELATED: Hemophilia newcomer Bioverativ aims to keep parent Biogen's 'patient-centric' corporate image

Payers, too, are looking to prioritize meds that can help improve outcomes, and especially with painwhich is a “huge epidemic-like problem for the U.S. and many other developed countries,” Peacock said“[U]nderstanding pain outcomes and whether or not they’re addressed by a drug is critical for those payers.”

Incorporating the new research into trial design, meanwhile, aligns with the “patient-centric” corporate image Bioverativ’s execs said they wanted to take with them from Biogen. "Biogen has, I think, a terrific corporate brand that is about putting the patient first, and it's about innovation, and we’ll carry that forward absolutely," Bioverativ CEO John Cox said in a January interview.

Suggested Articles

Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company's overall performance.

J&J has received its fair share of barbs Oklahoma's bench trial. Whether it'll be held responsible for the state's opioid crisis is now up…

J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.